EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY

Editor

PROFESSOR H. J. TAGNON

Volume 25, 1989

List of Contents and Author Index

PERGAMON PRESS

OXFORD · NEW YORK · BEIJING · FRANKFURT · SÃO PAULO · SYDNEY · TOKYO · TORONTO

European Journal of Cancer & Clinical Oncology

Subventionné par le Ministère de la Communauté Francophone de Belgique
Met de steun van de Ministerie van de Vlaamse Gemeenschap

Editor
Professor H. J. Tagnon, Institut Jules Bordet, rue Héger-Bordet, 1, 1000 Bruxelles, Belgique.
Tel.: (02) 538–27–66; *Fax*: 02/539.41.66

Editorial Secretary
Mrs. A. M. Stift

Co-Editors
J. Klastersky (Co-Editor for "Perspectives in Cancer Research and Commentaries"), H. M. Pinedo (Co-Editor for "New Drugs"), M. R. Price (Co-Editor for EACR) and W. Verly

Associate Editors

S. Garattini, *Milano*
P. Loustalot, *Basel*
G. Mathé, *Villejuif*
K. Munk, *Heidelberg*
P. Strauli, *Zürich*
D. W. van Bekkum, *Rijswijk*

Editorial Advisory Board

P. Alberto, *Genève (Switzerland)*
B. C. Baguley, *Auckland (New Zealand)*
P. Bentvelzen, *Rijswijk (The Netherlands)*
G. Bonadonna, *Milano (Italy)*
T. Boon, *Brussels (Belgium)*
R. D. Bulbrook, *London (U.K.)*
G. P. Canellos, *Boston, MA (U.S.A.)*
F. J. Cleton, *Leiden (The Netherlands)*
E. H. Cooper, *Leeds (U.K.)*
D. Crowther, *Manchester (U.K.)*
L. Denis, *Antwerpen (Belgium)*
T. M. Fliedner, *Ulm (F.R.G.)*
D. P. Griswold, *Birmingham, AL (U.S.A.)*
A. Hagenbeek, *Rijswijk (The Netherlands)*
H. H. Hansen, *Copenhagen (Denmark)*
K. R. Harrap, *Sutton (U.K.)*
B. Hoerni, *Bordeaux (France)*
V. C. Jordan, *Madison, WI (U.S.A.)*
F. Meunier, *Bruxelles (Belgium)*
H. T. Mouridsen, *Copenhagen (Denmark)*
C. G. Schmidt, *Essen (F.R.G.)*
P. Siegenthaler, *Neuchatel (Switzerland)*
J. F. Smyth, *Edinburgh (U.K.)*
F. Spreafico, *Milano (Italy)*
T. Philip, *Lyon (France)*
M. Tubiana, *Villejuif (France)*
E. Van der Schueren, *Leuven (Belgium)*
J. A. Van Dongen, *Amsterdam (The Netherlands)*
M. Van Glabbeke, *Brussels (Belgium)*
U. Veronesi, *Milano (Italy)*
D. D. Von Hoff, *San Antonio, TX (U.S.A.)*
R. Zittoun, *Paris (France)*
H. Zur Hausen, *Heidelberg (F.R.G.)*

Publishing & Advertising Offices: Headington Hill Hall, Oxford OX3 0BW (Oxford 64881)

Subscription rates (1990) (including postage and insurance) Annual institutional subscription rate (1990) DM 1490.00. 2 year institutional rate (1990/91) DM 2831.00. Personal subscription rate for those whose library subscribes at the regular rate (1990) DM 220.00. Prices are subject to change without notice. Twelve issues, published monthly. Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A., and for the remainder of the world to Pergamon Press plc, Headington Hill Hall, Oxford OX3 0BW, U.K.

Copyright © 1990 Pergamon Press plc

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organizations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

Photocopying information for users in the U.S.A. The Item-Fee Code for this publication indicates that authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service provided the stated fee for copying, beyond that permitted by Section 107 or 108 of the United States Copyright Law, is paid. The appropriate remittance of $3.00 per copy per article is paid directly to the Copyright Clearance Center Inc., 27 Congress Street, Salem, MA 01970.

Permission for other use. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying.

The Item-Fee Code for this publication is: 0277–5379/89$3.00 + 0.00

Back issues of all previously published volumes are available direct from Pergamon Press offices.

The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

LIST OF CONTENTS

NUMBER 1, JANUARY 1989

	1	**Editorial**
Perspectives in Cancer Research *J. Wils* and *H. Bleiberg*	3	**Current status of chemotherapy for gastric cancer**
Perspectives and Commentaries *D. N. Carney*	9	**Immunohistology of lung cancer**
F. Villani, M. Galimberti, R. Comazzi and *F. Crippa*	13	**Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin)**
F. Grief, H. S. Soroff, K. M. Albers and *L. B. Taichman*	19	**The effect of trifluoperazine, a calmodulin antagonist, on the growth of normal and malignant epidermal keratinocytes in culture**
R. Chibber and *M. J. Ord*	27	**The mutagenic and carcinogenic properties of three second generation antitumour platinum compounds: a comparison with cisplatin**
F. H. Dexeus, A. Shirkhoda, C. J. Logothetis, C. Chong, A. Sella, S. Ogden and *D. Swanson*	35	**Clinical and radiological correlation of retroperitoneal metastasis from nonseminomatous testicular cancer treated with chemotherapy**
C. J. van Groeningen, G. J. Peters and *H. M. Pinedo*	45	**Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer**
M. Caleffi, I. S. Fentiman and *B. G. Birkhead*	51	**Factors at presentation influencing the prognosis in breast cancer**
E. M. Cormier and *V. C. Jordan*	57	**Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor**
P. D. Rye and *R. A. Walker*	65	**Analysis of glycoproteins released from benign and malignant human breast: changes in size and fucosylation with malignancy**
A. P. van den Berg, J. L. Wike-Hooley, M. P. Broekmeyer-Reurink, J. van der Zee and *H. S. Reinhold*	73	**The relationship between the unmodified initial tissue pH of human tumours and the response to combined radiotherapy and local hyperthermia treatment**
H. Saito, T. Morizane, Y. Inagaki, N. Kumagai, T. Watanabe, T. Nakamura, I. Satoh, K. Sawaguchi, N. Iwabuchi, K. Tsuchimoto and *M. Tsuchiya*	79	**Decrease of transplantability by the immunopotentiators, OK-432 and interleukin-2: experiments on a human hepatoma cell line in nude mice**
M. Tatsuta, H. Iishi, H. Yamamura, M. Baba, T. Mikoni and *H. Taniguchi*	91	**Protective effect of oral cysteamine against induction of gastric cancer by *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine in Wistar rats**
H. A. Neumann, D. B. Herrmann, H. H. Fiebig and *R. Engelhardt*	99	**Treatment of human clonogenic tumor cells and bone marrow progenitor cells with bleomycin and peplomycin under 40.5°C hyperthermia *in vitro***
B. Betsch, M. R. Berger, B. Spiegelhalder, G. Eisenbrand and *D. Schmähl*	105	**New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities?**
A. Carbone, A. Poletti, R. Manconi, M. Cozzi, S. Sulfaro, V. Zagonel, U. Tirelli and *R. Volpe*	113	**Intermediate lymphocytic lymphoma encompassing diffuse and mantle zone pattern variants**
L. G. M. Jørgensen, H. H. Hansen and *E. H. Cooper*	123	**Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer**
O. Mogensen and *J. Møller*	129	**False positive results in an enzyme immunometric assay for the ovarian cancer associated antigen CA 125**
M. L. Neale and *N. Matthews*	133	**Development of tumour cell resistance to tumour necrosis factor does not confer resistance to cytotoxic drugs**
Clinical Trials Summaries *A. S. T. Planting, M. E. L. van der Burg, A. M. Hoff, J. Verweij* and *G. Stoter*	139	**A phase II study of high dose ifosfamide in metastatic colorectal cancer**
D. B. Smith and *A. Howell*	141	**A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer**
Letters to the Editor *L. C. Müller, G. M. Salzer, H. Frommhold, H. Denz* and *H. Huber*	145	**Therapy of small cell lung cancer: the use of surgery**
D. Y. Wang	147	**Prolactin and breast cancer**
Special Articles *W. Boogerd, J. J. van der Sande, R. Kröger, P. F. Bruning* and *R. Somers*	149	**Effective systemic therapy for spinal epidural metastases from breast carcinoma**

A. Robinson and *W. Jones*	155	**Changes in scalp hair after cancer chemotherapy**
Announcement	157	
EJCCO Service	i	
Software Survey Section	I	

NUMBER 2, FEBRUARY 1989

Perspectives and Commentaries *D. E. Bergsagel*	159	**Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?**
D. Bron and *P. Stryckmans*	163	**Removal of tumour cells from bone marrow: overview**
D. Thierry, P. Validire, M. Hardy, H. Magdelenat and *J. M. Zucker*	167	**Long term bone marrow culture in metastatic neuroblastoma**
I. N. Olver, D. Dalley, R. Woods, R. Aroney, P. Hughes, J. F. Bishop and *D. Cruickshank*	173	**Carboplatin and continuous infusion 5-fluorouracil for advanced head and neck cancer**
A. Horwich, M. Brada, J. Nicholls, G. Jay, W. F. Hendry, D. Dearnaley and *M. J. Peckham*	177	**Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours**
C. R. Hamilton, J. M. Bliss and *A. Horwich*	185	**The late effects of *cis*-platinum on renal function**
M. Frenay, G. Milano, N. Renee, D. Pons, R. Khater, E. François, A. Thyss and *M. Namer*	191	**Pharmacokinetics of weekly low dose doxorubicin**
C. L. Sinoff and *A. Blumsohn*	197	**Spinal cord compression in myelomatosis: response to chemotherapy alone**
T. Yano, K. Yasumoto and *K. Nomoto*	201	**Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer**
V. Silingardi, S. Davolio-Marani, M. Federico, L. Piccinini, A. Frassoldati, M. Sarti, A. Burani and *G. Canossi*	209	**Bone marrow infiltration in hairy cell leukemia after interferon therapy detected by magnetic resonance imaging**
G. Emons, G. S. Pahwa, C. Brack, R. Sturm, F. Oberheuser and *R. Knuppen*	215	**Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata**
M. W. Caldironi, D. Nitti, M. Schiavon, C. R. Rossi, M. T. Aldinio and *B. Azzena*	223	**Laparoscopy in the abdominal staging of melanoma**
S. Edström, T. Westin, U. Delle and *K. Lundholm*	227	**Cell cycle distribution and ornithine decarboxylase activity in head and neck cancer in response to enteral nutrition**
M. Samadi-Baboli, G. Favre, E. Blancy and *G. Soula*	233	**Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells *in vitro***
L. L. Shek and *W. Godolphin*	243	**Survival with breast cancer: the importance of estrogen receptor quantity**
K. Holli and *M. Hakama*	251	**Effectiveness of routine and spontaneous follow-up visits for breast cancer**
L. R. Ferguson, P. van Zijl and *B. C. Baguley*	255	**Mutagenicity profiles of newer amsacrine analogues with activity against solid tumours: comparison of microbial and mammalian systems**
B. C. Baguley, S. B. Calveley, K. K. Crowe, L. M. Fray, S. A. O'Rourke and *G. P. Smith*	263	**Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor α on Colon 38 tumours in mice**
G. J. Finlay and *B. C. Baguley*	271	**Selectivity of *N*-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines *in vitro***
P. Dodion, D. de Valeriola, J. J. Body, M. Houa, P. Noel, J. Abrams, N. Crespeigne, F. Wery and *Y. Kenis*	279	**Phase I clinical trial with carbetimer**
H. H. Bartsch, K. Pfizenmaier, M. Schroeder and *G. A. Nagel*	287	**Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies**
N. Knebel, C.-D. Schiller, M. R. Schneider, H. Schönenberger and *E. von Angerer*	293	**Carrier mediated action of platinum complexes on estrogen receptor positive tumors**

O. Stål, S. Wingren, J. Carstensen, L. E. Rutqvist, L. Skoog, C. Klintenberg and *B. Nordenskjöld*	301	**Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer**
J. M. Cook, A. T. Florence, J. Russell and *T. E. Wheldon*	311	**Etoposide (VP-16) uptake by tumour spheroids and activity in the presence of Brij 30, formulation additives and sodium salicylate**
G. Andry, S. Suciu, D. Pratola, R. Sylvester, G. Leclercq, P. M. da Costa, N. Legros, M. Andry-t'Hooft, A. Verhest, W. Mattheiem and *J.-C. Heuson*	319	**Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancer**
M. Fukuoka, N. Masuda, K. Matsui, M. Takada, S. Negoro, Y. Kusunoki, N. Sakai, S. Ryu, N. Takifuji and *H. Yamamoto*	331	**Three-year disease-free survivors of small cell lung cancer treated with combination chemotherapy with or without chest irradiation**
H. F. A. Vasen, W. Bergman, A. van Haeringen, E. Scheffer and *E. A. van Slooten*	337	**The familial dysplastic nevus syndrome**
D. A. Pratt, W. R. Miller and *J. Dawes*	343	**Thrombospondin in malignant and non-malignant breast tissue**
A. Courdi, M. Héry, E. Dahan, J. Gioanni, M. Abbes, J. Monticelli, F. Ettore, J.-L. Moll and *M. Namer*	351	**Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index**
W. G. Jones	357	**Effective palliation of advanced breast cancer with weekly low dose epirubicin**
F. B. Klugmann, G. Decorti, L. Candussio, F. Mallardi, V. Grill, M. Zweyer and *L. Baldini*	361	**Amelioration of 4'-epidoxorubicin-induced cardiotoxicity by sodium cromoglycate**
P. F. Bruning, J. M. G. Bonfrer, A. A. M. Hart, E. van der Linden, M. de Jong-Bakker, A. J. Moolenaar and *W. J. Nooijen*	369	**Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer**
Short Communication		
P. E. Postmus, H. Haaxma-Reiche, H. H. Berendsen and *D. Th. Sleijfer*	377	**High-dose etoposide for meningeal carcinomatosis in patients with small cell lung cancer**
Clinical Trials Summaries		
M. G. Pfreundschuh, H. T. Steinmetz, R. Tüschen, V. Schenk, V. Diehl and *M. Schaadt*	379	**Phase I study of intratumoral application of recombinant human tumor necrosis factor**
S. D. Fosså, T. Splinter, K. J. Roozendaal, K. H. N. Veenhof, M. Pavone-Macaluso, A. Calciati, M. de Pauw and *R. Sylvester*	389	**A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer**
G. Blackledge, J. T. Roberts, S. Kaye, R. Taylor, J. Williams, B. de Stavola and *B. Uscinska*	391	**A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder**
Letter to the Editor		
E. Chelmicka-Schorr and *M. E. Checinski*	393	**Sympathetic nervous system derived trophic factor augments growth of human neuroblastoma *in vitro***
Special Article		
A. de Schryver	395	**Does screening for cervical cancer affect incidence and mortality trends?**
Announcement	401	**Second International Conference on Melanoma**
Software Survey Section	I	

NUMBER 3, MARCH 1989

Perspectives in Cancer Research		
G. Contesso, G. S. Jotti and *G. Bonadonna*	403	**Tumor grade as a prognostic factor in primary breast cancer**
G. Giaccone	411	**Identification of new drugs in pretreated patients with small cell lung cancer**
P. B. D. Jacobs, M. Ruevekamp, F. J. Varossiau, G. A. M. Hart and *P. W. de Graaf*	415	**Alterations in serum levels, anti-tumor activity and toxicity of methotrexate in rats after a short period of nutritional depletion**
P. Hurteloup, J. P. Armand, M. Schneider, P. Bastit, B. Chevallier, C. Pourny, R. Keiling, C. de Oliveira, M. Hayat, D. Thomas, M. van Glabbeke, P. Rebattu and *G. Mathé*	423	**Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer**

S. Sekiya, T. Oosaki, S. Andoh, N. Suzuki, M. Akaboshi and *H. Takamizawa*	429	**Mechanisms of resistance to *cis*-diamminedichloroplatinum(II) in a rat ovarian carcinoma cell line**
B. G. Taal, F. C. A. den Hartog Jager, J. M. V. Burgers, P. van Heerde and *T. L. Tio*	439	**Primary non-Hodgkin's lymphoma of the stomach: changing aspects and therapeutic choices**
A. de Gramont, Y. Drolet, C. Varette, C. Louvet, G. Gonzalez-Canali, M. Krulik, J. Cady, A. Pigne, L. Marpeau, J. Barrat, D. Gallot, M. Malafosse and *J. Debray*	451	**Survival after second-look laparotomy in advanced ovarian epithelial cancer**
A. D. Baildam, A. Howell, D. M. Barnes, L. Turnbull and *R. A. Sellwood*	459	**The expression of milk fat globule antigens within human mammary tumours: relationship to steroid hormone receptors and response to endocrine treatment**
J. F. R. Robertson, M. R. Williams, J. Todd, R. I. Nicholson, D. A. L. Morgan and *R. W. Blamey*	469	**Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy**
T. Kusumoto, Y. Maehara, Y. Sakaguchi and *K. Sugimachi*	477	**Hyperthermia enhances the *in vitro* activity of 1-hexylcarbamoyl-5-fluorouracil compared to that of 5-fluorouracil**
M. Thörn, H.-O. Adami, U. Ringborg, R. Bergström and *U.-B. Krusemo*	483	**The association between anatomic site and survival in malignant melanoma. An analysis of 12,353 cases from the Swedish Cancer Registry**
S. P. Robinson and *V. C. Jordan*	493	**The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure**
P. Eker	499	**Effects of epidermal growth factor, fibroblast growth factor, retinoic acid and serum on anchorage-dependent and anchorage-independent growth of HRRT cells**
R. Bugat, J. Robert, A. Herrera, M. C. Pinel, S. Huet, C. Chevreau, G. Boussin, J. Roquain and *M. Carton*	505	**Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients**
H. J. Senn, A.-R. Barett-Mahler, W. F. Jungi and *OSAKO*	513	**Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results**
J. Carmichael, W. G. Degraff, J. Gamson, D. Russo, A. F. Gazdar, M. L. Levitt, J. D. Minna and *J. B. Mitchell*	527	**Radiation sensitivity of human lung cancer cell lines**
S. Berger, K.-H. Pflüger, W. A. Etzel and *J. Fischer*	535	**Detection of tumours with nuclear magnetic resonance spectroscopy of plasma**
J. Hermans, S. Suciu, Th. Stijnen, P. Aegerter, N. C. Gorin, A. Gratwohl, M. Hayat, P. Stryckmans, R. Zittoun and *F. E. Zwaan*	545	**Treatment of acute myelogenous leukemia**
S. Culine, M. Henry-Amar, J. Diebold, A. A. Audebert, G. Chomette, P. Prudhomme de Saint-Maur, B. Hoerni, J. Rojouan, A. Bernadou, R. Zittoun and *A. Najman*	551	**Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial**
J. J. McKendrick, G. M. Mead, J. Sweetenham, D. H. Jones, C. J. Williams, R. Ryall and *J. M. A. Whitehouse*	557	**ChlVPP chemotherapy in advanced Hodgkin's disease**
Short Communication		
D. A. Vorobiof and *G. Falkson*	563	**Phase II study of high-dose 4'-epidoxorubicin in the treatment of advanced gastrointestinal cancer**
Sounding Board		
H. W. Verspaget, J. H. Verheijen, P. A. F. de Bruin, G. Griffioen and *C. B. H. W. Lamers*	565	**Plasminogen activators in (pre)malignant conditions of the colorectum**
Letters to the Editor		
O. Russello, A. Romanini, D. Civalleri, R. Rosso, A. Nicolin and *A. Sobrero*	571	**Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, *in vitro***
C. R. Lewis, A. Jardine, E. M. Rankin and *S. B. Kaye*	573	**Autonomic neuropathy following treatment with flavone acetic acid**
Announcement	575	**National Cancer Institute (NCI)–European Organization for Research and Treatment of Cancer (EORTC) Research Training Program**
Errata	577	
EORTC News and Reports	i	

Software Survey Section I

NUMBER 4, APRIL 1989

Obituary 579

Acknowledgements 581

Perspectives in Cancer Research
G. Saccani Jotti and *G. Bonadonna* 585 **The pathologist and the clinical oncologist: a new effective partnership in assessing tumor prognosis**

Commentaries
R. Keller 599 **Adoptive immunotherapy of cancer with macrophages: current approaches and further prospects**

N. Blau, G. Schoedon and *H.-Ch. Curtius* 603 **Biosynthesis and significance of neopterin in the immune system**

C. S. Landefeld and *L. Goldman* 607 **The value of autopsy in modern oncology**

H. S. Reinhold and *A. E. van den Berg-Blok* 611 **Differences in the response of the microcirculation to hyperthermia in five different tumours**

P. A. Andrews, M. P. Murphy and *S. B. Howell* 619 **Characterization of cisplatin-resistant COLO 316 human ovarian carcinoma cells**

J. Verweij, M. E. L. van der Burg, W. L. van Putten, S. C. Henzen-Logmans, E. Salewski, H. P. Kraemer and *G. Stoter* 627 **Phase I studies of rodorubicin single bolus and daily times five, once every three weeks in patients with advanced solid tumors**

V. J. Richardson, C. H. J. Ford, G. Tsaltas and *M. E. Gallant* 633 **Doxorubicin–anti-carcinoembryonic antigen immunoconjugate activity *in vitro***

J. Andersen, H. Skovbon and *H. S. Poulsen* 641 **Immunocytochemical determination of the estrogen-regulated protein *M*, 24,000 in primary breast cancer and response to endocrine therapy**

P. O. M. Mulder, P. H. B. Willemse, J. G. Aalders, E. G. E. de Vries, D. Th. Sleijfer, C. Th. S. Sibinga and *N. H. Mulder* 645 **High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer**

K. J. Walker, R. F. Walker, A. Turkes, J. F. R. Robertson, R. W. Blamey, K. Griffiths and *R. I. Nicholson* 651 **Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer**

H. Nolte, S. B. Gjedde, E. Lindegaard-Madsen, J. Bergh, E. Blomquist and *H. T. Mouridsen* 655 **Phase II study of tauromustine in disseminated malignant melanoma**

G. B. Zulian and *R. O. Mirimanoff* 659 **Ten-year nodular sclerosis Hodgkin's disease and second malignancies**

R. D. Rubens, H. Bartelink, E. Engelsman, J. L. Hayward, N. Rotmensz, R. Sylvester, E. van der Schueren, J. Papadiamantis, S. D. Vassilaros, J. Wildiers and *P. J. Winter* 667 **Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy**

P. Buc-Calderon, M. Praet, J. M. Ruysschaert and *M. Roberfroid* 679 **Increasing therapeutic effect and reducing toxicity of doxorubicin by *N*-acyl dehydroalanines**

A. Vestergaard, J. Herrstedt, H. S. Thomsen, P. Dombernowsky and *K. Zedeler* 687 **The value of yearly chest X-ray in patients with stage I breast cancer**

M. R. Schneider, H. Michna, Y. Nishino and *M. F. El Etreby* 691 **Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat**

R. H. S. Liang, E. K. W. Woo, Y.-L. Yu, D. Todd, T.-K. Chan, F. C. S. Ho, S.-C. Tso and *J. S. T. Shum* 703 **Central nervous system involvement in non-Hodgkin's lymphoma**

E. E. Voest, J. C. van Houwelingen and J. P. Neijt 711 **A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives**

T. C. K. Chan and *S. B. Howell* 721 **Unexpected synergy between *N*-phosphonacetyl-L-aspartate and cytidine against human tumor cells**

F. Bessho 729 **Acute non-lymphocytic leukemia is not a major type of childhood leukemia in Japan**

S. W. Hansen, S. Groth, P. G. Sørensen, N. Rossing and *M. Rørth*	733	**Enhanced pulmonary toxicity in smokers with germ-cell cancer treated with *cis*-platinum, vinblastine and bleomycin: a long-term follow-up**
G. Falkson and *H. C. Falkson*	737	**CAF and nasal buserelin in the treatment of premenopausal women with metastatic breast cancer**
M. Volm, T. Efferth, M. Bak, A. D. Ho and *J. Mattern*	743	**Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin–biotinylated phycoerythrin complex method**
Clinical Trials Summaries		
C. Sessa, S. B. Kaye, J. Renard, W. ten Bokkel Huinink and *F. Cavalli*	751	**Phase II study of intravenous menogaril in advanced ovarian carcinoma**
C. N. Sternberg, A. Yagoda, H. Scher, G. Bosl, D. Dershaw, K. Rosado, C. Houston, R. Rosenbluth, V. Vinciguerra, B. Boselli and the Clinical Community Oncology Program	753	**Phase II trial of trimetrexate in patients with advanced renal cell carcinoma**
J. F. Smyth, S. Gundersen, J. Renard and *H. M. Pinedo*	755	**Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma**
Letters to the Editor		
E. Sulis, C. Floris, M. L. Sulis, S. Zurrida, S. Piro, A. Pintus and *L. Contu*	759	**Interferon administered intralesionally in skin and oral cavity lesions in heterosexual drug addicted patients with AIDS-related Kaposi's sarcoma**
W. Scheithauer, H. Ludwig, R. Kotz and *D. Depisch*	763	**Mitoxantrone-induced discoloration of the nails**
Special Article		
K. Schaapveld and *F. J. Cleton*	767	**Cancer in The Netherlands**
Announcement	773	**EACR-X—Tenth Meeting of the European Association for Cancer Research**
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 5, MAY 1989

Commentary		
S. B. Howell	775	**Improving the therapeutic index of intra-arterial cisplatin chemotherapy**
A. Hijazi, M. Devonec, R. Bouvier, G. Escourrou, A. Longin, P. Perrin and *J.-P. Revillard*	777	**Phenotyping of 76 human bladder tumors with a panel of monoclonal antibodies: correlation between pathology, surface immunofluorescence and DNA content**
M. Harding, V. Docherty, R. Mackie, A. Dorward and *S. Kaye*	785	**Phase II studies of mitozolomide in melanoma, lung and ovarian cancer**
P. Lissoni, S. Barni, S. Crispino, G. Tancini and *F. Fraschini*	789	**Endocrine and immune effects of melatonin therapy in metastatic cancer patients**
J. G. Kuhn, D. D. von Hoff, M. Hersh, T. Melink, G. M. Clark, G. R. Weiss and *C. A. Coltman*	797	**Phase I trial of echinomycin (NSC 526417), a bifunctional intercalating agent, administered by 24-hour continuous infusion**
A. Costa, W. Malone, M. Perloff, F. Buranelli, T. Campa, G. Dossena, A. Magni, M. Pizzichetta, C. Andreoli, M. Del Vecchio, F. Formelli and *A. Barbieri*	805	**Tolerability of the synthetic retinoid Fenretinide® (HPR)**
S. Noguchi, K. Miyauchi, H. Inaji, S. Imaoka and *H. Koyama*	809	**Enzyme immunoassay of estrogen and progesterone receptors in drill biopsy specimens from breast cancer**
P. Canal, R. Bugat, E. Chatelut, M.-C. Pinel, G. Houin, Y. Plusquellec and *M. Carton*	815	**Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26)**
L.-M. Ching and *B. C. Baguley*	821	**Effect of flavone acetic acid (NSC 347 512) on splenic cytotoxic effector cells and their role in tumour necrosis**
B. Glimelius, K. Hoffman, M. Olafsdottir, L. Påhlman, P.-O. Sjödén and *A. Wennberg*	829	**Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens**

R. Kiss, Y. de Launoit, W. Wouters, J. P. Deslypere, J. P. Lescrainier, R. Paridaens, A. Vokaer, R. Decoster and *J. L. Pasteels*	837	**Inhibitory action of androstenedione on the proliferation and cell cycle kinetics of aromatase-free MXT and MCF-7 mammary tumour cell lines**
W. Dobrowsky, E. Dobrowsky, H. Strassl, O. Braun and *V. Scheiber*	845	**Response to preoperative concomitant radio-chemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer**
N. S. El Saghir, K. Jessen, R. E. Mass, I. Al-Mofleh, C. R. Santhosh-Kumar, A. D. Hall and *A. E. Stuart*	851	**Combination chemotherapy for primary small intestinal lymphoma in the Middle East**
H. Bleiberg, B. Gerard, Ph. Peetrons and *P. Dodion*	857	**Measurements of response to chemotherapy using ultrasound in metastatic liver involvement**
Y. Bécouarn, R. Brunet and *C. Barbé-Gaston*	861	**Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary**
D. Y. Wang, H. Hamed, C. I. Mockridge and *I. S. Fentiman*	867	**Radioimmunoassayable insulin-like growth factor-I in human breast cyst fluid**
S. S. Bielack, R. Erttmann, K. Winkler and *G. Landbeck*	873	**Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy**
Y. Sidi, E. Beery, C. Panet, L. Wassermann, A. Novogrodsky and *J. Nordenberg*	883	**Growth inhibition and induction of phenotypic alterations by tiazofurin: differential effects on MCF-7 breast cancer and HBL-100 breast cell lines**
S. Dauvois, P. G. Spinola and *F. Labrie*	891	**Additive inhibitory effects of bromocryptine (CB-154) and medroxy-progesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat**
A. Österborg, H. Ehrsson, S. Eksborg, I. Wallin and *H. Mellstedt*	899	**Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients**
Clinical Trials Summaries		
P. Alberto, J. J. Winkelmann, N. Paschoud, R. Peytremann, A. Bruyere, A. Righetti, G. Decoster and *E. E. Holdener*	905	**Phase I study of oral doxifluridine using two schedules**
G. Anderson, M. Clavel, J. Smyth, G. Giaccone, M. Gracia, A. S. Planting, O. Dalesio, A. Kirkpatrick and *G. McVie*	909	**Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung**
J. Carmichael, B. M. J. Cantwell and *A. L. Harris*	911	**A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma**
Sounding Board		
J. A. Green	913	**After Goldie–Coldman—where now?**
Letters to the Editor		
B. M. J. Cantwell, J. Carmichael, K. A. Mannix and *A. L. Harris*	917	**Chemotherapy induced emesis may exacerbate the nephrotoxicity of combined ifosfamide/mesna and cisplatin chemotherapy**
W.-Y. Lui, F.-K. P'eng, T.-J. Chang, H.-L. Kao, T.-Y. Liu and *C.-W. Chi*	919	**Ischemia effect on the level of steroid hormone receptors in hepato-cellular carcinoma and adjacent liver tissue**
Announcement	921	**Hodgkin Disease EORTC Symposium**
Books Received	923	
Software Survey Section	I	

NUMBER 6, JUNE 1989

Commentaries		
E. T. Fossel	925	**Commentary on 'Detection of tumors with nuclear magnetic resonance spectroscopy of plasma' by S. Berger, K.-H. Pflüger, W. A. Etzel, J. Fischer**
J. Klastersky	929	**Intensive chemotherapy in SCLC**
J. Hüttner N. Wiener, C. Quadt, K.-H. Dallüge, H. Grunau, S. Tanneberger and *K. Merkle*	933	**A randomized clinical trial comparing systemic radiotherapy versus chemotherapy versus local radiotherapy in small cell lung cancer**
P. Carde, M. F. Cosset-Delaigue, A. Laplanche and *I. Chareau*	939	**Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors**
R. B. Lichtner, G. Hutchinson and *K. Hellmann*	945	**The pyrimido-pyrimidine derivatives RA233 and RX-RA85 affect cell cycle distribution of two murine tumour cell lines**

P. B. Dunki Jacobs, M. Ruevekamp, G. A. M. Hart and *P. W. de Graaf*	953	**Dietary influences on cell proliferation in bone marrow**
K. Collett, R. Skjærven, T. Thorsen, F. Hartveit and *B. O. Mæhle*	959	**The prognostic role of progesterone receptor status and age in relation to axillary node status in breast cancer patients**
R. A. Stahel, J. P. Sculier, L. M. Jost, A. Delforge, D. Bron, J. Gmür, O. Oelz, C. Sauter, P. Stryckmans and *J. Klastersky*	965	**Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors**
Z. T. Cossack	973	**T-Lymphocyte dysfunction in the elderly associated with zinc deficiency and subnormal nucleoside phosphorylase activity: effect of zinc supplementation**
A. Sobrero, A. Romanini, O. Russello, A. Nicolin, R. Rosso and *J. R. Bertino*	977	**Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction**
L. Damstrup, G. Daugaard, J. Gerstoft and *M. Rørth*	983	**Effects of antineoplastic treatment of HIV-positive patients with testicular cancer**
C. Sauter and *C. Wolfensberger*	987	**Anticancer activities as well as antiviral and virus-enhancing properties of aqueous fruit extracts from fifty-six European plant species**
D. B. Smith, J. A. Ledermann, E. Boesen, E. S. Newlands, R. H. J. Begent, G. J. S. Rustin, M. G. Glaser and *K. D. Bagshawe*	991	**EMOP/CA chemotherapy for the treatment of aggressive non-Hodgkin's lymphomas**
Clinical Trials Summaries		
P. Hurteloup, P. Chollet. H. Roche, B. Chevallier, P. Cappelaere, M. van Glabbeke, M. Hayat and *J. P. Armand*	995	**Phase II trial of esorubicin in advanced renal carcinoma**
S. Bindemann, C. Bolund, M. Sullivan and *N. Aaronson*	997	**Report on the Second Scientific Meeting of the European Society for Psychosocial Oncology (ESPO), Amsterdam, October 24th, 25th 1988**
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 7, JULY 1989

Perspectives		
A. M. Gianni and *G. Bonadonna*	1027	**High dose chemo-radiotherapy for sensitive tumors: is sequential better than concurrent drug delivery?**
Commentaries		
E. A. Tueni	1031	**Human tumor clonogenic assay: what is new?**
J. Klastersky	1035	**Chemotherapy in non-small cell lung cancer (NSCLC)**
S. Niitamo-Korhonen, P. Holsti, L. R. Holsti, S. Pyrhönen and *K. Mattson*	1039	**A comparison of *cis*-platinum–vindesine and *cis*-platinum–etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer**
F. Boomsma, L. Ausema, F. G. A. Hakvoort-Cammel, R. Oosterom, A. J. Man in 't Veld, E. P. Krenning, K. Hahlen and *M. A. D. H. Schalekamp*	1045	**Combined measurements of plasma aromatic L-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma**
J. Treat, S. C. Falchuk, C. Tremblay, M. Spielman, P. V. Woolley, J. Rouesse, D. Sevin and *T. le Chevalier*	1053	**Phase II trial of methotrexate–FAM (m-FAM) in adenocarcinoma of unknown primary**
E. Chelmicka-Schorr, M. E. Checinski and *B. G. W. Arnason*	1057	**PC12 pheochromocytoma and sympathetic nervous system derived trophic factors augment growth of neuroblastoma**
L.-M. Ching and *B. C. Baguley*	1061	**Reduction of cytotoxic effector cell activity in Colon 38 tumours following treatment with flavone acetic acid**
S. Rasoul-Rockenschaub, C. C. Zielinski, E. Kubista, N. Vavra, E. Pospischil, A. Staffen, K. Czerwenka, P. Aiginger and *J. Spona*	1067	**Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer**
J. A. Levi, D. Thomson, J. Bishop, D. Raghavan, M. Tattersall, M. Byrne, G. Gill, V. Harvey, R. Snyder, D. Dalley and *T. Sandeman*	1073	**Dose intensity and outcome with combination chemotherapy for germ cell carcinoma**

B. W. Borjesson, M. N. Cauchi, P. J. Compton, T. M. S. Foo, C. Gramacho, R. Hähnel, K. P. Ho, I. M. Holdaway, D. J. Horsfall, T. H. Lie, J. M. Lentern, J. G. Lewis, R. McGinley, J. Milliken, P. Pearce, V. Pitsiavas, C. Smyth, J. F. Speed and *B. Wyatt*	1079	**Identification of the major sources of error in estrogen receptor measurements for individual laboratories using both tissue and cytosol samples**
B. W. Borjesson, M. N. Cauchi, P. J. Compton, P. A. Elder, T. M. S. Foo, C. Gramacho, R. Hähnel, L. C. Harrison, I. M. Holdaway, D. J. Horsfall, A. R. Kennerson, T. H. Lie, J. M. Lentern, R. McGinley, P. Pearce, V. Pitsiavas, C. Smyth, J. F. Speed and *B. Wyatt*	1087	**Sources of improvement in between laboratory variation in estrogen and progestin receptor measurements using tissue samples during the Australasian Quality Assurance Programme**
S. Gundersen, P. Dombernowsky, F. Cavalli, U. Bruntsch, J. Renard, M. van Glabbeke and *H. Pinedo*	1095	**TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer**
R. T. Mulcahy, J. J. Gipp, A. Carminati, J.-L. Barascut and *J.-L. Imbach*	1099	**Chemosensitization at reduced nitroimidazole concentrations by mixed-function compounds combining 2-nitroimidazole and chloroethyl-nitrosourea**
A. L. Harris, B. M. J. Cantwell, J. Carmichael, P. Dawes, A. Robinson, J. Farndon and *R. Wilson*	1105	**Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer**
H. G. Keizer, S. J. de Leeuw, J. van Rijn, H. M. Pinedo and *H. Joenje*	1113	**Effect of artificial electron acceptors on the cytotoxicity of mitomycin C and doxorubicin in human lung tumor cells**
Clinical Trials Summaries		
J. Wils, H. Bleiberg. M. Buyse, D. Th. Wagener, T. Splinter, C. Veenhof, M. Herben and *N. Duez*	1119	**An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas**
Letters to the Editor		
J. Bonneterre and *J. P. Peyrat*	1121	**Prolactin receptors (PRL-R) and breast cancer**
G. J. G. Rees	1123	**Is alcohol intolerance in cancer patients explained by tumour production of alcohol dehydrogenase?**
Books Received	1125	
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 8, AUGUST 1989

Commentaries		
J. Carlsson and *T. Nederman*	1127	**Tumour spheroid technology in cancer therapy research**
S. L. Kelley and *M. Rozencweig*	1135	**Resistance to platinum compounds: mechanisms and beyond**
H. Höfeler and *M. E. Scheulen*	1141	**Monitoring of patients with nonseminomatous testicular cancer by nuclear magnetic resonance spectroscopy of plasma**
A. Marfella, V. Ruocco, A. Capobianco, M. Perna, G. Santelli, G. Frigione, S. K. Kyalwazi, R. D. Mugerwa, D. Serwadda, E. Beth-Giraldo and *G. Giraldo*	1145	**Neopterin and alpha-interferon in patients affected by Kaposi's sarcoma from Africa**
A. Zaniboni, E. Simoncini, P. Marpicati, E. Montini, V. Ferrari, A. Ferragni, L. Boari and *G. Marini*	1151	**Cyclophosphamide, epirubicin, high-dose folinic acid and 5-fluorouracil (super-FEC) as first-line chemotherapy for advanced breast cancer: preliminary results**
J. van der Zee, M. P. Broekmeyer-Reurink, A. P. van den Berg, B. N. van Geel, R. F. M. Jansen, B. B. R. Kroon, J. van Wijk and *A. Hagenbeek*	1157	**Temperature distribution and pH changes during hyperthermic regional isolation perfusion**
R. Silvestrini, M. G. Daidone, P. Valagussa, G. di Fronzo, G. Mezzanotte and *G. Bonadonna*	1165	**Cell kinetics as a prognostic indicator in node-negative breast cancer**
J. W. van Dongen, G. J. van Steenbrugge, J. C. Romijn and *F. H. Schröder*	1173	**The cytocidal effect of high energy shock waves on human prostatic tumour cell lines**
E. Oksenhendler, P. Landais, C. Cordonnier, M. Kuentz, M. Bagot, J.-P. Jais, J.-C. Roujeau and *J.-P. Vernant*	1181	**Acral erythema and systemic toxicity related to CHA induction therapy in acute myeloid leukemia**

O. Mogensen, B. Mogensen and *A. Jakobsen*	1187	**CA 125 in the diagnosis of pelvic masses**
K. Takenaka, T. Kanematsu, M. Shimada and *K. Sugimachi*	1191	**Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma**
H. Roed, K. Aabo, L. Vindeløv, M. Spang-Thomsen, I. J. Christensen and *H. H. Hansen*	1197	***In vitro* and *in vivo* evaluation of the indoloquinone EO-9 (NSC 382 459) against human small cell carcinoma of the lung**
R. Otter, W. B. J. Gerrits, M. M. V. D. Sandt, J. Hermans and *R. Willemze*	1203	**Primary extranodal and nodal non-Hodgkin's lymphoma**
L. R. Kelland and *K. S. Tonkin*	1211	***In vitro* chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity**
K. Heimdal, E. Hannisdal and *S. Gundersen*	1219	**Regression analyses of prognostic factors in metastatic malignant melanoma**
H. Iguchi, N. Hara, I. Hayashi, M. Ohta, S. R. Bloom and *M. Chrétien*	1225	**Elevation of a novel pituitary protein (7B2) in the plasma in small cell carcinoma of the lung**
F. Spyratos, K. Hacène, M. Tubiana-Hulin, C. Pallud and *M. Brunet*	1233	**Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer**
K. Vantongelen, N. Rotmensz and *E. van der Schueren*	1241	**Quality control of validity of data collected in clinical trials**
Clinical Trial Summaries		
A. T. van Oosterom, G. Stoter, A. V. Bono, T. A. W. Splinter, S. D. Fossa, A. J. Verbaeys, P. H. M. de Mulder, M. de Pauw and *R. Sylvester*	1249	**Mitozolomide in advanced renal cancer**
W. P. Steward, H. T. Mouridsen, P. Kerbrat, R. Somers, J. Verweij, A. T. van Oosterom, G. Blackledge, H. Havsteen, D. Thomas and *R. Sylvester*	1251	**Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult**
Letters to the Editor		
D. Newling, M. R. G. Robinson, L. Denis and *R. Sylvester*	1255	**Standardized objective criteria of response—comments on 'Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma' by Labrie F. *et al.*****
F. Labrie	1259	
Books Received	1261	
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 9, SEPTEMBER 1989

Perspectives in Cancer Research		
B. L. Hillcoat	1263	**Priorities in experimental therapeutics—a surfeit of riches**
Commentary		
D. J. Kerr and *S. B. Kaye*	1271	**Flavone acetic acid—preclinical and clinical activity**
H. W. Bruckner, C. J. Cohen, S. Bhardwaj, E. Feuer, M. R. Chesser and *J. F. Holland*	1273	**Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer**
G. Nicoletti, C. de Giovanni, P.-L. Lollini, G. P. Bagnara, K. Scotlandi, L. Landuzzi, B. del Re, G. Zauli, G. Prodi and *P. Nanni*	1281	***In vivo* and *in vitro* production of haemopoietic colony-stimulating activity by murine cell lines of different origin: a frequent finding**
D. T. J. Liley, P. M. Wiggins and *B. C. Baguley*	1287	**Localization of a nonintercalative DNA binding antitumour drug in mitochondria: relationship to multidrug resistance**
G. Svaninger, J. Gelin and *K. Lundholm*	1295	**The cause of death in non-metastasizing sarcoma-bearing mice**
S. W. Watkin, D. J. Husband, J. A. Green and *H. M. Warenius*	1303	**Ifosfamide encephalopathy: a reappraisal**
J. A. Boutin, K. Norbeck, P. Moldeus, A. Genton, M. Paraire, J.-P. Bizzari, G. Lavielle and *C. A. Cudennec*	1311	**Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues *in vivo* and in isolated rat hepatocytes**

J. F. Hamming, C. J. H. van de Velde, B. M. Goslings, L. J. D. M. Schelfhout, G. J. Fleuren, J. Hermans and *A. Zwaveling*	1317	**Prognosis and morbidity after total thyroidectomy for papillary, follicular and medullary thyroid cancer**
M. V. Pimm, L. G. Durrant and *R. W. Baldwin*	1325	**Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model**
Clinical Trial Summaries		
H. Seinen, B. A. Zonnenberg, P. Tjia and *J. P. Neijt*	1333	**The effect of three dose levels of ICS 205-930 (a selective 5HT-3 antagonist) on cisplatin-induced nausea and vomiting**
P. Berthaud, T. Le Chevalier, J. Berille, P. Herait, P. Baldeyrou, T. Tursz, R. Arriagada, M. Spielmann and *M. Hayat*	1337	**Phase II study of pirarubicin in advanced non-small cell lung cancer**
G. Falkson and *S. Ansell*	1339	**Phase II trial of buserelin in hepatocellular carcinoma**
International Conference on Supportive Care in Oncology		
S. C. Schimpff and *J. Klastersky*	1343	**Introduction**
J. Verhoef, M. Rozenberg-Arska and *A. W. Dekker*	1345	**Prevention of bacterial and fungal infections in granulocytopenic patients**
S. C. Schimpff	1351	**Dilemmas and choices in infection management of the cancer patient**
M. P. Glauser	1359	**Immunotherapy of gram-negative infections in oncological patients**
D. Bron and *J. Klastersky*	1365	**Immunoprophylaxis of cytomegalovirus infections in transplanted patients**
J. D. Meyers	1369	**Chemoprophylaxis of viral infection in immunocompromised patients**
K. A. Newman, W. P. Reed, C. I. Bustamante, S. C. Schimpff and *J. C. Wade*	1375	**Venous access devices utilized in association with intensive cancer chemotherapy**
D. P. Lew	1379	**Physiopathology of foreign body infections**
W. P. Reed, K. A. Newman and *J. C. Wade*	1383	**Choosing an appropriate implantable device for long-term venous access**
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 10, OCTOBER 1989

Short Review		
Z. H. Siddik, M. J. Edwards and *A. W. Boddie*	1393	**Isolated limb perfusion with chemotherapeutic agents for melanoma: a reevaluation of drug dosimetry**
Commentary		
J. Dagnelie, M. Lemort and *M. C. Segebarth*	1399	**Nuclear magnetic resonance: a diagnostic aid in oncology**
E. Bork, S. Vest and *H. H. Hansen*	1403	**A phase I clinical and pharmacokinetic study of Brequinar sodium, DUP 785 (NSC 368390), using a weekly and a biweekly schedule**
P. M. Mannucci, M. Cattaneo, M. T. Canciani, M. Maniezzo, M. Vaglini and *N. Cascinelli*	1413	**Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma)**
S. Hill, K. B. Williams and *J. Denekamp*	1419	**Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action**
G. Søndergaard, K. O. Pedersen and *S. M. Paulsen*	1425	**Estrogen receptor analyses in breast cancer: comparison of monoclonal immunohistochemical and biochemical methods**
S. Lauk, S. Skates, M. Goodman and *H. D. Suit*	1431	**A morphometric study of the vascularity of oral squamous cell carcinomas and its relation to outcome of radiation therapy**
U. Vitolo, M. Bertini, C. Tarella, M. C. Bertoncelli, A. Gallamini, E. Gallo, A. M. Gatti, R. Ghio, A. Levis, G. Luxi, L. Marchi, A. Novarino, E. Orlandi, L. Orsucci, F. Ricciuti, D. Rota-Scalabrini, E. Scassa, C. Bernasconi, A. Pileri and *L. Resegotti*	1441	**MACOP-B treatment for advanced stage diffuse large cell lymphoma: a multicenter Italian study**
F. Parazzini, E. Negri, C. La Vecchia, P. Bruzzi and *A. Decarli*	1451	**Population attributable risk for endometrial cancer in northern Italy**

I. N. Olver, L. K. Webster, J. F. Bishop, J. Clarke and *B. L. Hillcoat*	1457	**A dose finding study of prochlorperazine as an antiemetic for cancer chemotherapy**
H. D. Suit, S. Rockwell, A. Zeitman, V. Silobrcic, E. A. Porter, J. Ramsay and *R. Sedlacek*	1463	**Quantitative transplantation assays of the rat rhabdomyosarcoma BA1112 isografts into the WAG/Rij Y rat and xenotransplantation into the athymic NCr(nu/nu) nude mouse**
P. B. S. Silcocks, H. Thornton-Jones and *R. G. Skeet*	1467	**Making cancer statistics more informative: measures of the quality of recorded diagnosis in a population-based registry**
K. Öberg, I. Norheim and *G. Alm*	1475	**Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon**
F. R. Balkwill, D. B. Griffin and *A. E. Lee*	1481	**Interferons alpha and gamma differ in their ability to cause tumour stasis and regression *in vivo***
M. A. Burton, B. N. Gray, P. F. Klemp, D. K. Kelleher and *N. Hardy*	1487	**Selective internal radiation therapy: distribution of radiation in the liver**
T. Yamamoto, M. Fukuoka, T. Yasumura and *H. Okada*	1493	***In vivo* and *in vitro* effects of the antifungal agent miconazole on estrogen biosynthesis in human breast cancer**
W. Distelmans, R. van Ginckel, W. Vanherck, R. Willebrords, M. de Brabander, L. Wouters and *J. Heeres*	1499	**Influence of the synthetic microtubule inhibitor erbulozole (P.I.N.N.) (R 55 104), a new tubulozole congener, and gamma irradiation on murine tumors *in vivo***
Clinical Trial Summaries		
A. van der Gaast, T. C. Kok, N. H. van der Linden and *T. A. W. Splinter*	1505	**Intrapericardial instillation of bleomycin in the management of malignant pericardial effusion**
P. Berthaud, T. Le Chevalier, J. Berille, P. Herait, P. Baldeyrou, T. Tursz, R. Arriagada, M. Spielmann and *M. Hayat*	1507	**Phase II study of pirarubicin in advanced non-small cell lung cancer**
E. G. E. de Vries, A. G. Nanninga, J. Greidanus, E. Th. H. G. J. Oremus, R. C. J. Verschueren, N. H. Mulder, D. Th. Sleijfer and *P. H. B. Willemse*	1509	**A phase II study of a 21 day continuous infusion schedule with epirubicin in advanced gastric cancer**
Letter to the Editor		
W. C. Cosolo and *N. Christophidis*	1511	**An example of the role of the animal model in investigating new techniques**
Special Article		
L.-M. Ching and *B. C. Baguley*	1513	**Hyporesponsiveness of macrophages from C_3H/HeJ (endotoxin-resistant) mice to the antitumour agent flavone acetic acid (NSC 347512)**
EORTC News and Reports	i	
Software Survey Section	I	

NUMBER 11, NOVEMBER 1989

H. J. Tagnon	1517	**A message from the Editor**
Commentaries		
C. B. Begg, L. Pilote and *P. B. McGlave*	1519	**Bone marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: a meta-analytic review**
W. H. Fridman	1525	**New immunotherapeutic approaches: the use of cytokines to stimulate the immune system or to control the growth of malignant lymphoid cells**
G. Recondo, M. Benhamed, E. Cvitkovic, P. Marandas and *J. P. Armand*	1529	**96-Hour continuous infusion of *cis*-platinum, 5-fluorouracil and bleomycin in recurrent or metastatic head and neck squamous cell carcinoma, unexpected anemia**
G. Frykholm, B. Glimelius and *L. Påhlman*	1535	**Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum**
D. Schuster, M. E. Heim, G. Decoster and *W. Queißer*	1543	**Phase I–II trial of doxifluridine (5'dFUR) administered as long-term continuous infusion using a portable infusion pump for advanced colorectal cancer**
S. K. Howell, L. C. Stephens and *Y.-M. Wang*	1549	**Daunorubicin-induced mammary tumors in the rat**
W. Meier, W. Eiermann, P. Stieber, A. Schneider, A. Fateh-Moghadam and *H. Hepp*	1555	**Experiences with SCC antigen, a new tumor marker for cervical carcinoma**

G. J. Ossenkoppele, P. W. Wijermans, F. C. de Waal, T. A. M. v. d. Berg, W. Jalink, P. C. Huijgens and *M. M. A. C. Langenhuijsen*	1561	**Low dose cytosine-arabinoside has only minimal differentiation inducing capacity in HL60 cells**
T. W. J. Lennard, A. L. Harris, J. Hales, A. Dickinson, R. Wolstencroft. P. Halcrow, B. K. Shenton, M. McDonald, G. F. Lawrence and *R. M. R. Taylor*	1571	**A phase I study of immunostimulation and toxicity in patients with colorectal carcinoma using the immunomodulator 3,6-bis(2-piperidino-ethoxy) acridine trihydrochloride (CL 246738)**
G. Semenzato, F. Siviero, F. Vinante, R. Zambello, L. Trentin, C. Agostini, F. Adami, C. Vincenzi, R. Zanotti, B. Zuppini, M. Chilosi and *G. Pizzolo*	1577	**Serum levels of soluble CD8 are increased in patients with B chronic lymphocytic leukemia**
T. Giraldi, L. Perissin, S. Zorzet, P. Piccini and *V. Rapozzi*	1583	**Effects of stress on tumor growth and metastasis in mice bearing Lewis lung carcinoma**
A. Jakobsen and *P. Bichel*	1589	**Ploidy level, histopathological differentiation and response to chemotherapy in serous ovarian cancer**
P. Bevilacqua, M. Pea and *G. Gasparini*	1595	**Immunocytochemical detection of progesterone receptor by monoclonal KD-68 antibody in operable breast cancer: correlations with biochemical assay, pathological features and cell proliferative rate**
R. R. Gala, S. Martino, S. A. Wiejowski, C. L. Kresge and *M. del Mar Alonso*	1603	**Serum interleukin 2 (IL-2) levels and prolactin bioactive/radioimmunoassay ratios of women at risk for breast cancer**
V. Combaret, Q. Wang, M. C. Favrot, P. Thiesse, I. Philip, E. Bouffet, C. Bailly, R. Bouvier, F. Chauvin, J. M. Zucker, J. L. Bernard, G. Lenoir and *T. Philip*	1607	**Clinical value of N-myc oncogene amplification in 52 patients with neuroblastoma included in recent therapeutic protocols**
C. La Vecchia, F. Parazzini, E. Negri, P. Boyle, A. Gentile, A. Decarli and *S. Franceschi*	1613	**Breast cancer and combined oral contraceptives: an Italian case-control study**
J. L. Tatman, R. S. Freedman, W. Scott and *E. Neely Atkinson*	1619	**Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate**
J. L. Mansi, I. E. Smith, G. Walsh, R. P. A'Hern, C. L. Harmer, H. D. Sinnett, P. A. Trott, C. Fisher and *J. A. McKinna*	1623	**Primary medical therapy for operable breast cancer**
J. Haveman and *A. A. M. Hart*	1629	**The relationship between treatment duration and temperature for hyperthermia induced lethality of cultured murine cells**
A. K. Ghosh, T. Cerny, J. Wagstaff, N. Thatcher and *M. Moore*	1637	**Effect of *in vivo* administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma**
B. Zafrani, P. Vielh, A. Fourquet, V. Mosseri, J. C. Durand, R. J. Salmon and *J. R. Vilcoq*	1645	**Conservative treatment of early breast cancer: prognostic value of the ductal *in situ* component and other pathological variables on local control and survival**
Clinical Trial Summary *T. Le Chevalier, C. Zabbe, S. Gouva, M. L. Cerrina, E. Quoix, A. Riviere, P. Berthaud, C. Prache* and *J. Berille*	1651	**Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma**
Letter to the Editor *J. Bourhis, O. Hartmann, J. Benard, C. Kalifa* and *G. Riou*	1653	**Relapse from a stage IV-S neuroblastoma and N-*myc* amplification**
Special Article *Q. J. Walker, G. Salkeld, J. Hall, I. O'Rourke, C. A. Bull, K. W. Tiver* and *A. O. Langlands*	1657	**The management of oesophageal carcinoma: radiotherapy or surgery?**
Meeting Abstracts	1663	**The Second Annual Meeting of the Danish Society for Cancer Research**
Announcement	1671	
Erratum	1673	
Software Survey Section	I	

NUMBER 12, DECEMBER 1989

I	**Notice to Contributors**
III	**Thank you, Professor Tagnon**

G. Schwartsmann, W. J. F. van der Vijgh, M. B. van Hennik, I. Klein, J. B. Vermorken, P. Dodion, W. W. ten Bokkel Huinink, G. Joggi, H. Gall, N. Crespeigne, G. Simonetti, B. Winograd and *H. M. Pinedo*	1675	**Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study**
M. E. Fallowfield	1683	**Blood flow distribution within transplantable tumours in the mouse**
M. J. Harding, I. L. Brown, S. G. Macpherson, M. A. Turner and *S. B. Kaye*	1689	**Excision of residual masses after platinum based chemotherapy for non-seminomatous germ cell tumours**
G. J. Finlay, W. R. Wilson and *B. C. Baguley*	1695	**Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs**
F. Bach, F. W. Bach, A. G. Pedersen, P. M. Larsen and *P. Dombernowsky*	1703	**Creatine kinase-BB in the cerebrospinal fluid as a marker of CNS metastases and leptomeningeal carcinomatosis in patients with breast cancer**
C. La Vecchia, E. Negri, F. Parazzini, P. Boyle, M. Fasoli, A. Gentile and *S. Franceschi*	1711	**Alcohol and breast cancer: update from an Italian case-control study**
E. Anderson, H. Morten, D. Y. Wang, P. Burns, J. Birch and *A. Howell*	1719	**Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives**
M. Satoh, N. Miura, A. Naganuma, N. Matsuzaki, E. Kawamura and *N. Imura*	1727	**Prevention of adverse effects of γ-ray irradiation after metallothionein induction by bismuth subnitrate in mice**
E. Kjellén, R. W. Pero, P. Nilsson and *S. A. Hill*	1733	**Effect of hyperthermia and/or nicotinamide on the radiation response of a C3H mammary carcinoma**
K. S. Tonkin, G. J. S. Rustin, B. Wignall, F. Paradinas and *M. Bennett*	1739	**Successful treatment of patients in whom germ cell tumour masses enlarged on chemotherapy while their serum tumour markers decreased**
E. S. Gussetis, U. Ebener, S. Wehner and *B. Kornhuber*	1745	**Immunological detection and definition of minimal residual neuroblastoma disease in bone marrow samples obtained during or after therapy**
C. Cavalli, M. Danova, P. G. Gobbi, A. Riccardi, U. Magrini, G. Mazzini, D. Bertoloni, L. Rutigliano, A. Rossi and *E. Ascari*	1755	**Ploidy and proliferative activity measurement by flow cytometry in non-Hodgkin's lymphomas. Do speculative aspects prevail over clinical ones?**
L. Wasserman, E. Beery, R. Aviram, H. Levavi, J. Ovadia, A. Novogrodsky and *J. Nordenberg*	1765	**Sodium butyrate enhances the activities of membranal enzymes and increases drug sensitivity in a cell line from ascitic fluid of an ovarian carcinoma patient**
S. P. Robinson, S. M. Langan-Fahey and *V. C. Jordan*	1769	**Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts**
C. S. Murphy, L. F. Meisner, S. Q. Wu and *V. C. Jordan*	1777	**Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture**
R. E. Clark, A. D. Geddes, J. A. Whittaker and *A. Jacobs*	1789	**Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma**
A. Gabizon, T. Peretz, A. Sulkes, S. Amselem, R. Ben-Yosef, N. Ben-Baruch, R. Catane, S. Biran and *Y. Barenholz*	1795	**Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study**
S. Longstaff, H. Sigurdsson, M. O'Keeffe, S. Ogston and *P. Preece*	1805	**A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma**
N. R. Pratt, R. C. Rees and *C. W. Potter*	1809	***In vivo* tumour × host cell fusion in spontaneous Syrian hamster metastasis**
G. Robustelli della Cuna, A. Pellegrini and *M. Piazzi*	1817	**Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study**
T. Popiela, R. Lucchi and *F. Giongo*	1823	**Methylprednisolone as palliative therapy for female terminal cancer patients**
J. J. Body, A. Magritte, A. Cleeren, A. Borkowski and *P. Dodion*	1831	**Short-term effects of carbetimer on calcium and bone metabolism in man**
I. A. Adamietz, F. Kurfürst, U. Müller, K. Renner and *M. Rimpler*	1837	**Growth acceleration of Ehrlich ascites tumor cells treated by proteinase *in vitro***
E. R. Clark, S. P. Robinson, E. M. Whitaker and *J. A. Zoltowski*	1843	**The effect of pregnant mares serum gonadotrophin on the response of DMBA induced rat mammary tumours to tamoxifen or oestrogen**
J. Nelson, M. McGivern, B. Walker, J. R. Bailie and *R. F. Murphy*	1851	**Growth-inhibitory and growth-stimulatory effects of epidermal growth factor on human breast cancer cell line, MDA.MB.436: dependence on culture conditions**

G. Los, M. Ruevekamp, N. Bosnie, P. W. de Graaf and *J. Gordon McVie*	1857	**Intraperitoneal tumor growth and chemotherapy in a rat model**
G. R. Weiss, G. A. Sarosy, T. D. Shenkenberg, T. Williams, N. J. Clendeninn, D. D. von Hoff, J. L. Woolley, S. H. T. Liao and *M. R. Blum*	1867	**A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U)**
M. Ohsawa, K. Aozasa, Takashi Tsujimura, H. Ikeda and *Takahiro Tsujimura*	1875	**Non-Hodgkin's lymphomas of follicular center cell type in Osaka, Japan**
Clinical Trial Summaries		
R. J. M. da Luz and *R. D. Rubens*	1879	**Norethisterone acetate as secondary endocrine treatment in advanced breast cancer**
J. Vibe-Petersen, F. Bach, A. G. Pedersen, J. Smyth and *H. H. Hansen*	1881	**A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung**
A. S. T. Planting, E. A. Runhaar, J. Verwey, B. G. Taal, G. Blijham and *J. P. Neyt*	1887	**Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study**
A. T. van Oosterom, J. P. Droz, S. T. Fossa, A. V. Bono, T. A. W. Splinter, A. J. Verbaeys, J. Keizer, M. de Pauw and *R. Sylvester*	1889	**TCNU in advanced renal cancer**
G. Blackledge, J. Verweij, R. Fuchs, H. J. Keizer, R. Somers, E. Rankin, P. Kerbrat, A. van Oosterom, R. Sylvester, D. Thomas and *J. Rouesse*	1891	**A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma**
Letters to the Editor		
P. Ubezio, M. Limonta, M. D'Incalci, G. Damia, G. Masera, G. Giudici, J. S. Wolverton and *W. T. Beck*	1895	**Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia**
M. Buyse and *M. K. B. Parmar*	1901	
S. Sommer, E. B. Thorling, A. Jakobsen, E. Steiness and *K. Østergaard*	1903	**Can bismuth decrease the kidney toxic effect of *cis*-platinum?**
Special Articles		
EuroCODE Steering Committee	1905	**EuroCODE: a new approach to collaborative research in clinical oncology**
D. J. Perry, S. M. Hubbard and *R. J. Young*	1907	**PDQ: a new source of information on cancer therapy**
B. A. Stoll	1909	**Hormone replacement therapy in women treated for breast cancer**
Papers from the European Organization for Cooperation in Cancer Prevention Studies Annual Symposium Breast, Endometrial and Ovarian Cancer: Aetiological and Epidemiological Relationships		
D. Maxwell Parkin	1917	**Cancers of the breast, endometrium and ovary: geographic correlations**
M. Ewertz and *H. H. Storm*	1927	**Multiple primary cancers of the breast, endometrium and ovary**
S. Franceschi	1933	**Reproductive factors and cancers of the breast, ovary and endometrium**
C. La Vecchia	1945	**Nutritional factors and cancers of the breast, endometrium and ovary**
J. H. H. Thijssen and *M. A. Blankenstein*	1953	**Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues**
F. E. van Leeuwen and *M. A. Rookus*	1961	**The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer**
Books Received	1973	
EORTC News and Reports	i	
Software Survey Section	I	

SUPPLEMENT 1, 1989
PROCEEDINGS OF THE ONDANSETRON SYMPOSIUM

Preface *J. F. Smyth*	S3	
Section 1 *R.J. Gralla*	S7	**An outline of anti-emetic treatment**
Discussion	S13	
M.B. Tyers, K.T. Bunce and *P.P.A. Humphrey*	S15	**Pharmacological and anti-emetic properties of ondansetron**
C.P. Blackwell and *S.M. Harding*	S21	**The clinical pharmacology of ondansetron**
Discussion	S25	
T.J. Priestman	S29	**Clinical studies with ondansetron in the control of radiation-induced emesis**
H.-J. Schmoll	S35	**The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes**
M. Marty	S41	**Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting**
R.N. Smith	S47	**Safety of ondansetron**
Discussion	S51	
Summary *J.F. Smyth*	S55	
Section 2 *J.W.M. Mackinnon* and *D.T. Collin*	S61	**The chemistry of ondansetron**
R.E. Leak and *J.D. Woodford*	S63	**Pharmaceutical development of ondansetron tablets**
R.E. Leak and *J.D. Woodford*	S67	**Pharmaceutical development of ondansetron injection**
P.V. Colthup and *J.L. Palmer*	S71	**The determination in plasma and pharmacokinetics of ondansetron**
D.A. Saynor and *C.M. Dixon*	S75	**The metabolism of ondansetron**
M.L. Tucker, M.R. Jackson, M.D.C. Scales, N.W. Spurling, D.J. Tweats and *K. Capel-Edwards*	S79	**Ondansetron: Pre-clinical safety evaluation**

SUPPLEMENT 2, 1989
MANAGEMENT OF INFECTIONS IN IMMUNOCOMPROMISED PATIENTS

R. Feld	S1	**The compromised host**
P. A. Pizzo	S9	**Evaluation of fever in the patient with cancer**
J. C. Pechère	S17	**Emergence of resistance in gram-negative bacilli during β-lactam therapy: a challenge for the future**
D. J. Winston, W. G. Ho and *R. Ł. Champlin*	S25	**Current approaches to management of infections in bone marrow transplants**
G. J. Lieschke, D. Bell, W. Rawlinson, M. D. Green, W. Sheridan, G. Morstyn, R. Stuart-Harris, R. F. Kefford, J. Levi, T. Sorrell and *R. M. Fox*	S37	**Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview**
J. W. Hathorn	S43	**Empirical antibiotics for febrile neutropenic cancer patients**
J. Klastersky	S53	**Infections in compromised hosts: considerations on prevention**
T. F. Patterson and *V. T. Andriole*	S63	**The role of liposomal amphotericin B in the treatment of systemic fungal infections**

SUPPLEMENT 3, 1989
PROLEUKIN® (rIL-2): FROM RESEARCH TO REALITY

Preface *T. J. Hamblin*	S5	
T. J. Hamblin	S7	**Clinical parameters for evaluating biological response modifier therapy**
W. H. West	S11	**Clinical application of continuous infusion of recombinant interleukin-2**
Renal Cell Cancer *C. Rugarli*	S19	**Progress in therapy of renal cell cancer**
S. Negrier, T. Philip, G. Stoter, S. D. Fossa, S. Janssen, A. Iacone, F. S. Cleton, O. Eremin, L. Israel, C. Jasmin, C. Rugarli, H. V. D. Masse, N. Thatcher, M. Symann, H. H. Bartsch, L. Bergmann, J. T. Bijman, P. A. Palmer and *C. R. Franks*	S21	**Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study**
Malignant Melanoma *L. Bergmann*	S31	**Malignant melanoma – prognosis and actual treatment strategies with chemotherapy and biological response modifiers**
G. Parmiani and *L. Rivoltini*	S37	***In vitro* lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols**
G. Stoter, E. Shiloni, S. Aamdal, F. J. Cleton, S. Iacobelli, J. Th. Bijman, P. Palmer, C. R. Franks and *S. Rodenhuis*	S41	**Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study.**
E. Shiloni, P. Pouillart, J. Janssens, T. Splinter, T. Di Peri, M. Symann, G. J. Roest, P. A. Palmer and *C. R. Franks*	S45	**Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I–II study.**